tradingkey.logo
tradingkey.logo
Search

24H|Abivax Shares Surged 22% As To Attract Interest From Eli Lilly

TigerJan 12, 2026 8:24 AM
facebooktwitterlinkedin
View all comments0

Abivax Shares Surged 22% As To Attract Interest From Eli Lilly

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme (NASDAQ:ABVX), TheFly reported.

Thefly revealed on December 18, 2025, that Guggenheim analyst Yatin Suneja has increased the company’s price objective for ABIVAX Société Anonyme (NASDAQ:ABVX) from $150 to $175. The analyst maintained a Buy rating for the stock. Guggenheim’s positive forecast for obefazimod ahead of an impending 44-week maintenance readout is the basis for the price target hike.

The firm has €589.7 million in cash despite high R&D-driven losses and a €15.3 million monthly cash burn.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.